U.S., Dec. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07268638) titled 'A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)' on Nov. 26.
Brief Summary: This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS). Participants will be randomized 1:1 to receive praliciguat or placebo for initial 24 week treatment period. Following this double-blind period, all participants will receive praliciguat in an open-label extension for an additional 24 weeks.
Study Start Date: Dec. 01
Study Type: INTERVENTIONAL
Condition: ...